Current Report Filing (8-k)
September 09 2019 - 8:31AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): September 9, 2019
NEUROTROPE, INC.
(Exact name of registrant as specified
in its charter)
Nevada
|
000-55275
|
46-3522381
|
(State or other jurisdiction
of incorporation)
|
(Commission File Number)
|
(IRS Employer
Identification No.)
|
1185 Avenue of the Americas, 3rd Floor
New York, New York 10036
(Address of principal executive offices and zip code)
Registrant’s telephone number,
including area code: (973) 242-0005
(Former Name or Former Address, if Changed
Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
Common Stock, par value $0.0001 per share
|
|
NTRP
|
|
The Nasdaq Stock Market
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company. ¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨
On September 9,
2019, Neurotrope, Inc. (the “Company”) issued a press release announcing that its confirmatory Phase 2 study of Bryostatin-1
in moderate to severe Alzeheimer’s disease (“AD”) did not achieve statistical significance on the primary endpoint,
which was change from baseline to Week 13 in the Severe Impairment Battery (“SIB”) total score.
An average increase
in SIB total score of 1.3 points and 2.1 points was observed for the Bryostatin-1 and placebo groups, respectively, at Week 13.
There were multiple secondary outcome measures in this trial, including the changes from baseline at Weeks 5, 9 and 15 in the SIB
total score. No statistically significant difference was observed in the change from baseline in SIB total score between the Bryostatin-1
and placebo treatment groups.
The confirmatory
Phase 2 multicenter trial was designed to assess the safety and efficacy of Bryostatin-1 as a treatment for cognitive deficits
in patients with moderate to severe AD — defined as a Mini Mental State Exam 2 score of 4-15 – who are not currently
taking memantine. Patients were randomized 1:1 to be treated with either Bryostatin-1 20μg or placebo, receiving 7 doses over
12 weeks. Patients on memantine, an NMDA receptor antagonist, were excluded unless they had been discontinued from memantine treatment
for a 30-day washout period prior to study enrollment. The primary efficacy endpoint was the change in the SIB score between the
baseline and week 13. Secondary endpoints included repeated SIB changes from baseline SIB at weeks 5, 9, 13 and 15.
A copy of the press release is attached
as Exhibit 99.1 to this report and is incorporated herein by reference.
|
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits.
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
NEUROTROPE, INC.
|
|
|
|
|
|
|
Date: September 9, 2019
|
By: /s/ Robert Weinstein
|
|
Name:
|
Robert Weinstein
|
|
Title:
|
Chief Financial Officer, Executive Vice President,
Secretary and Treasurer
|
NextTrip (NASDAQ:NTRP)
Historical Stock Chart
From Aug 2024 to Sep 2024
NextTrip (NASDAQ:NTRP)
Historical Stock Chart
From Sep 2023 to Sep 2024